Eysuvis, a new FDA-approved corticosteroid that is indicated for the short-term treatment, up to two weeks, of the signs and symptoms of dry eye disease. Patients often have periods of exacerbation called dry eye flares, where their dry eye symptoms can be triggered by digital screen time, seasonal allergies, contact lens wear, and AC use. […]
view more